Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1F | P30939 | 19/20 | 1.00 |
| ▸ | HTR1D | P28221 | 15/20 | 1.00 |
| ▸ | HTR1B | P28222 | 14/20 | 1.00 |
| ▸ | HTR1A | P08908 | 10/20 | 0.61 |
| ▸ | HTR2A | P28223 | 1/20 | 0.58 |
| ▸ | HTR2C | P28335 | 1/20 | 0.58 |
| ▸ | HTR1E | P28566 | 1/20 | 0.58 |
| ▸ | HTR6 | P50406 | 1/20 | 0.58 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7009821 | 0.86 | HTR1F (0.75) | HTR1FHTR1DHTR1BHTR1AHTR2A | |
| SCHEMBL7012811 | 0.85 | HTR1F (0.74) | HTR1FHTR1DHTR1BHTR1AHTR2A | |
| SCHEMBL7011498 | 0.85 | HTR1F (0.74) | HTR1FHTR1DHTR1BHTR1AHTR2A | |
| SCHEMBL7015495 | 0.84 | HTR1F (0.72) | HTR1FHTR1DHTR1BHTR1AHTR2A | |
| SCHEMBL7009081 | 0.83 | HTR1F (0.71) | HTR1FHTR1DHTR1BHTR1AHTR2A | |
| SCHEMBL7005580 | 0.82 | HTR1F (0.69) | HTR1FHTR1DHTR1BHTR1AHTR2A | |
| SCHEMBL4058392 | 0.82 | HTR1F (0.69) | HTR1FHTR1DHTR1BHTR1AHTR2A | |
| SCHEMBL7005021 | 0.81 | HTR1F (0.68) | HTR1FHTR1DHTR1BHTR1AHTR2A | |
| SCHEMBL7011996 | 0.81 | HTR1F (1.00) | HTR1FHTR1DHTR1BHTR1AHTR2A | |
| SCHEMBL7009425 | 0.80 | HTR1F (0.65) | HTR1FHTR1DHTR1BHTR1AHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0916669-B1 | Processes and intermediates for the preparation of Pyrrolo(3,2-b)pyridine | LILLY CO ELI (US) | 2003-04-09 | — | — | EP | claimed |
| CN-1278814-A | Pyrrolo [3,2-b] pyridine processes and intermediates | LILLY CO ELI (US) | 2001-01-03 | — | — | CN | claimed |
| US-6150525-A | Pyrrolo [3,2-b]pyridine processes and intermediates | ELI LILLY AND COMPANY (US) | 2000-11-21 | — | — | US | claimed |
| WO-1999025708-A1 | PYRROLO[3,2-b]PYRIDINE PROCESSES AND INTERMEDIATES | ELI LILLY AND COMPANY (US) | 1999-05-27 | — | — | WO | claimed |
| EP-0916669-A2 | Processes and intermediates for the preparation of Pyrrolo(3,2-b)pyridine | ELI LILLY AND COMPANY (US) | 1999-05-19 | — | — | EP | claimed |
| EP-0842934-B1 | 5-HT1F agonists | LILLY CO ELI (US) | 2003-10-29 | — | — | EP | disclosed |
| EP-0916670-B1 | Pyrrolo-(3,2-b) pyridines and their use as 5-HT1F agonists | LILLY CO ELI (US) | 2003-05-14 | — | — | EP | disclosed |
| EP-0916669-B1 | Processes and intermediates for the preparation of Pyrrolo(3,2-b)pyridine | LILLY CO ELI (US) | 2003-04-09 | — | — | EP | disclosed |
| EP-0916669-A3 | Processes and intermediates for the preparation of Pyrrolo(3,2-b)pyridine | ELI LILLY AND COMPANY (US) | 2001-05-23 | — | — | EP | disclosed |
| EP-1082958-A2 | 5-HT1F agonists in chronic pain | ELI LILLY AND COMPANY (US) | 2001-03-14 | — | — | EP | disclosed |
| CN-1284874-A | 5-HT1F agonists | LILLY CO ELI (US) | 2001-02-21 | — | — | CN | disclosed |
| CN-1278814-A | Pyrrolo [3,2-b] pyridine processes and intermediates | LILLY CO ELI (US) | 2001-01-03 | — | — | CN | disclosed |
| WO-1999025708-A1 | PYRROLO[3,2-b]PYRIDINE PROCESSES AND INTERMEDIATES | ELI LILLY AND COMPANY (US) | 1999-05-27 | — | — | WO | disclosed |
| WO-1999025708-A1 | PYRROLO[3,2-b]PYRIDINE PROCESSES AND INTERMEDIATES | ELI LILLY AND COMPANY (US) | 1999-05-27 | — | — | WO | disclosed |
| EP-0916669-A2 | Processes and intermediates for the preparation of Pyrrolo(3,2-b)pyridine | ELI LILLY AND COMPANY (US) | 1999-05-19 | — | — | EP | disclosed |
| EP-0916670-A2 | Pyrrolo-(3,2-b) pyridines and their use as 5-HT1F agonists | ELI LILLY AND COMPANY (US) | 1999-05-19 | — | — | EP | disclosed |
| EP-0916669-A2 | Processes and intermediates for the preparation of Pyrrolo(3,2-b)pyridine | ELI LILLY AND COMPANY (US) | 1999-05-19 | — | — | EP | disclosed |
| US-5905084-A | 5-SUBSTITUTED-3-(PIPERIDIN-4-YL)- AND -3-(1,2,3,6-TETRAHYDROPYRIDIN-4-YL)PYRROLO(3,2-B)PYRIDINES; SIDE EFFECT REDUCTION; NERVOUS SYTEM AND PSYCHOLOGICAL DISORDERS | ELI LILLY AND COMPANY (US) | 1999-05-18 | — | — | US | disclosed |
| US-5817671-A | ANTISEROTONIN AGENT; ANALGESICS; MIGRAINE THERAPY; COMPOUND CONTAINING PYRROLO(3,2-B)PYRIDINE RING | ELI LILLY AND COMPANY (US) | 1998-10-06 | — | — | US | disclosed |
| EP-0842934-A1 | 5-HT1F agonists | ELI LILLY AND COMPANY (US) | 1998-05-20 | — | — | EP | disclosed |